|
Oct 9
|
Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
|
|
Sep 4
|
Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 4
|
Journey Medical Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 4
|
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
|
Sep 3
|
Avenue Therapeutics to Participate in Upcoming Investor Conferences
|
|
Sep 2
|
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
|
|
Jul 25
|
Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027
|
|
Jul 25
|
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
|
|
Jun 24
|
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
|
|
Jun 21
|
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Jun 20
|
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
|
|
Jun 20
|
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Mar 28
|
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
|
|
Mar 28
|
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
|
|
Jan 11
|
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 11
|
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
|
|
Jan 9
|
Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...
|
|
Dec 6
|
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease, to Sentynl Therapeutics, a Wholly-owned Subsidiary of Zydus Lifesciences Ltd.
|
|
Dec 6
|
Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics
|